Notice & Comment

Results for: waivers

Notice & Comment

Fall 2017 Projects (ACUS Update)

The Administrative Conference of the United States will soon begin fall committee meetings on a slate of projects targeted for completion at the 68th annual plenary session, to be held in December.  These projects include: (1) Plain Language in Regulatory Drafting; (2) Agency Guidance; (3) Regulatory Waivers and Exemptions; and (4) Regulatory Experimentation.  A description (taken […]

Notice & Comment

FDA’s Reliance on User Fees

Cross-posted on Objective Intent. On August 18, the President signed the Food and Drug Administration Reauthorization Act of 2017 (FDARA), which reauthorized FDA to collect user fees in connection with new drugs, biologics, and medical devices for human use.  These user fee programs are colloquially known as PDUFA (innovator drugs and biologics), GDUFA (generic drugs), BsUFA […]

Notice & Comment

Call for Papers: Loyola Compliance Symposium “What is the Role of a Regulation if it is Not Enforced?”

Loyola Chicago has a terrific Center for Compliance Studies, which is directed by Ryan Meade. Last year I participated in the Center’s first annual symposium “Complying with Law: An Interdisciplinary Dialogue.” I’m fascinated by the field of compliance, and the role of lawyers — and administrative law — in it. Last year’s symposium was a terrific opportunity […]

Notice & Comment

When Adjudication is Avoiding Adjudication

Immigration law is tasked with determining who should be removed (deported) from the United States. Theoretically, that adjudication takes place before an immigration judge, who works for the Department of Justice. A lawyer for the Department of Homeland Security represents the government. There is a good chance the foreign national has no attorney, especially if […]

Notice & Comment

From Big Waiver to Waiver Unlimited

The Senate has now released the Better Care Reconciliation Act of 2017, its answer to the House’s American Health Care Act. The bill is wildly unpopular and has already come under fire from Senate Republicans, either for being too mean or not mean enough. But some version of the BCRA may still get 50 votes […]

Notice & Comment

The Michigan Morsel

To corral some last-minute votes, the House leadership has endorsed the Upton amendment to the American Health Care Act. The legislative text was released late yesterday, giving members no time to understand what it does before they vote on it today. That’s a shame: the amendment works at cross-purposes with other parts of the AHCA, […]

Notice & Comment

President Trump Signs Executive Order Introducing Significant Changes into the Federal Regulatory Process, by John Cooney

On January 30, President Trump issued an Executive Order entitled “Reducing Regulation and Controlling Regulatory Costs,” which if properly implemented may herald the most significant changes in the federal regulatory process since 1981, when President Reagan instituted formal White House Regulatory Review of rules issued by Executive departments and agencies. At this stage, analysis of […]

Notice & Comment

Executive actions Trump could take to change the ACA

This post was coauthored by Nicholas Bagley and Adrianna McIntyre.  The executive order President Trump signed on Friday does not have any immediate policy effect, but it does call attention to the wide range of administrative actions that a Trump administration could take to change the Affordable Care Act—all without legislation from Congress. We’ve compiled […]

Notice & Comment

The Trump Executive Order on the ACA

There are some misconceptions floating around about what the executive order does and doesn’t do. Let me try to clarify. As I explained in a post last week, “[a]uthority to implement the ACA … is vested in the Secretaries of HHS, Treasury, and Labor—not the President. In the context of the ACA, an executive order […]

Notice & Comment

The ABA AdLaw Section’s Report to the President-Elect: Adjudication Recommendations, by Michael Asimow

A Trump administration is unlikely to be supportive of three of the four recommendations relating to adjudication in the Report to the President-Elect by the ABA Section on Administrative Law and Regulatory Practice. Considering these recommendations (though not in the order they were presented in the ABA’s letter): 1) The Ad Law Section urged the […]

Notice & Comment

The IRS’s Private Equity Regulations Might Backfire

In a post last week , my co-blogger Daniel Hemel explained how Section 707(a)(2)(A) may allow the IRS to deny the tax benefits associated with so-called carried interests, even in the absence of legislative action. That statute essentially grants the IRS the regulatory authority to alter the tax treatment of transactions between partners and partnerships, […]

Notice & Comment

The IRS vs. Private Equity (Part 2)

In my previous post, I briefly discussed how the IRS has short-circuited the APA’s notice and comment rulemaking procedures to combat tax motivated transactions by private equity firms. I’d like to further flesh out that point here. Given the general readership of this blog, I’ll start by considering a hypothetical environmental statute and then turn […]